WO2004078223A1 - A new bone substitute composition - Google Patents
A new bone substitute composition Download PDFInfo
- Publication number
- WO2004078223A1 WO2004078223A1 PCT/SE2004/000328 SE2004000328W WO2004078223A1 WO 2004078223 A1 WO2004078223 A1 WO 2004078223A1 SE 2004000328 W SE2004000328 W SE 2004000328W WO 2004078223 A1 WO2004078223 A1 WO 2004078223A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- injectable composition
- calcium phosphate
- calcium sulfate
- composition
- component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0052—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with an inorganic matrix
- A61L24/0063—Phosphorus containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the invention refers to a composition for an artificial bone mineral substitute material as well as a bone mineral substitute material produced therefrom. More precisely, the invention relates to an injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at least one calcium sulfate component being particulate hardened calcium sulfate, which has a specified particle size in order to confer injectability to the composition.
- an injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at least one calcium sulfate component being particulate hardened calcium sulfate, which has a specified particle size in order to confer injectability to the composition.
- Bone is the second most common material to be transplanted after blood.
- the most reliable method to repair bone defects is to use autogenous bone, i.e. bone taken from another site in the body.
- problems may occur at the second surgical site where the graft is taken.
- allografts can be used, i.e. bone graft between individuals of the same species .
- Allografts have a lower osteogenic capacity than autografts and the rate of new bone formation might be lower. They also have a higher resorption rate, a larger immunogenic response and less revascularisation of the recipient. Allografts must also be controlled for viruses since they can transfer, for example, HIV and hepatitis. The use of allografts is now the most common method for bone transplantation and repairing of bone defects.
- Calcium sulfate hemihydrate CaS0 4 ⁇ H 2 ⁇
- the drawbacks are the rapid resorbtion and low strength, which makes it less useful in larger or non-contained defects and when the fracture healing exceeds 4—6 weeks .
- the dissolution rate of calcium sulfate has made it suitable as a carrier for drug release.
- pellets of calcium sulfate hemihydrate are shown, which are useful for controlled delivery of drugs. On implantation of a human or other animal, the pellets provide sustained and controlled delivery to a local site for periods ranging from 25 to 45 days.
- Calcium phosphates are suitable as bone substitutes because of their bioactive properties, i.e. having an effect on or obtaining response from living tissue. Their resorbtion rate is relatively slow, up to several years .
- CaP calcium phosphates
- CaP obtained by precipitation from an aqueous solution at room temperature low-temperature CaP
- CaP obtained by a thermal treatment high-temperature CaP
- Hydroxyapatite is the most stable calcium phosphate and the primary non-organic component of bone. Most of the bone graft substitutes on the market are made of hydroxyapatite. High temperature treated hydroxyapatite is highly crystalline and the least soluble of the calcium phosphates .
- Hydroxyapatite and tri-calcium phosphate are the most common calcium phosphates used to fill bone defects and as implant coatings. Their resorbtion rate is relatively slow, from six months to several years. It is possible to increase the rate of degradation slightly by increasing the surface area of the material, decreasing the crystallinity and the crystal perfection and decreasing the size of crystals and grains in the material. A higher resorbtion rate can be preferable to encourage bone formation.
- Bone mineral substitute materials can be prepared as a paste which can be injected directly into a fracture site.
- the paste is injected into the void in the bone and, upon hardening, an implant is obtained which conforms to the contours of the gap and supports the cancellous bone.
- Both calcium sulfate and hydroxyapatite materials have been extensively investigated as a possible alternative to autogenous bone grafts to help restore osseous defects of bone and fixation of bone fracture.
- a complete stability is obtained as quickly as possible during or after surgery in order to prevent motions at site of healing. This especially applies to fractures, but also when filling of a bone cavity or replacing bone lost during tumor removal the healing is inhibited by movements and the ingrowth of new bone is prevented.
- the injected material must cure fast and adhere firmly to the bone tissue.
- complications, such as infections can arise. Cavities may also be previously infected and have to be treated with for example antibiotics .
- the hardened material is so similar in structure to the bone so that it can be gradually resorbed by osteoclasts and replaced by new bone. This process can be facilitated if the hardened cement is provided with pores, which can transport nutrients and provide vascular ingrowth allowing new bone formation.
- CN 1193614 shows a porous calcium phosphate bone cement for repairing human hard tissue.
- the cement contains pore-forming agent which may be a non-toxic surfactant, or a nontoxic slightly soluble salt, acidic salt and alkaline salt.
- US 4,619,655 discloses a bone mineral substitute material comprising a mixture of calcium sulfate hemihydrate and calcium phosphate ceramic particles, preferably composed of hydroxyapatite, or tricalcium phosphate or mixtures thereof.
- the calcium sulfate hemihydrate was completely resorbed within a few weeks and replaced by connective tissue when material composed of 50/50 mixtures of hydroxyapatite/calcium sulfate hemihydrate were implanted into experimentally created defects in rat mandible. The hydroxyapatite was not resorbed and some particles were eventually completely surrounded by bone. It was therefore concluded that the calcium sulfate hemihydrate acted as filler and scaffold for the incorporation of hydroxyapatite into bone.
- the composition comprises essentially calcium sulfate hemihydrate with small amounts of calcium sulfate dihydrate .
- Organic and inorganic materials such as hydroxyapatite, can also be included in the composition. After hardening, particles of hydroxyapatite are obtained within a calcium sulfate cement. The calcium sulfate cement is dissolved rapidly by aqueous body fluids within four weeks, leaving solid particles of hydroxyapatite.
- compositions for use as an animal implant comprises calcium sulfate hemihydrate, calcium phosphate, and sodium sulfate.
- the calcium phosphate is hydroxyapatite and the sodium sulfate enables the composition to be used in the presence of blood or other body fluids .
- an injectable composition is shown, which. is useful for a bone mineral substitute material.
- the dry powder of the composition comprises calcium sulfate hemihydrate, calcium phosphate and at least one accelerator.
- the composition will harden during surgery with accompanying early control of fracture fragment movement.
- a stable lasting implant is provided, which has a higher mechanical strength than tra- becular bone, and the implant obtains with time a porous as well as irregular structure for bone in growth.
- the object of the invention is to provide a composition for a bone mineral substitute material, which is injectable, which hardens in a body fluid in vivo during surgery, and which provides a stable lasting implant over a year with high mechanical strength, whereby a porous structure is obtained, which size and formation can be controlled.
- Another object of the present invention is to provide such an improved bone mineral substitute composition for filling defects in osteoporotic bone and for additional fracture fixation in substantially cancellous bone, which does not exhibit the drawbacks of high viscosity at delivery.
- a further object of the invention is to provide a bone mineral substitute composition, which can be used with minimally invasive surgical techniques, which can be hardened in situ, and which results in stability of any defect geometry.
- Still another object of the invention is to provide a bone mineral substitute composition that has excellent biocompatibility as well as favorable biological and rheological properties.
- Yet still a further object of the invention is to provide a bone mineral substitute composition that is biodegradable and can be sterilized by radiation or gas without suffering a significant deterioration in properties .
- an injectable composition for a bone mineral substitute material which has the capability of being hardened in a body fluid in vivo .
- the injectable composition comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture, and an aqueous liquid mixed with the dry mixture.
- the at least one calcium sulfate component is particulate hardened calcium sulfate that has a diameter which is less than 100 ⁇ m, the injectability of the composition being guaranteed.
- the composition also comprises at least one accelerator.
- the particle diameter of the particulate hardened calcium sulfate is adapted to a size that is sufficiently small to allow for the composition to be injectable.
- a suitable particle diameter of the particulate hardened calcium sulfate is between 1 and 50 ⁇ m, preferably etween 1 and 10 ⁇ m. This means that the composition can be injected through a needle having a diameter of about 1-2 mm or even less.
- the particulate hardened calcium sulfate should comprise up to 60 wt%, preferably 10-40 wt% of the dry mixture of the injectable composition.
- the particulate hardened calcium sulfate is calcium sulfate dihydrate (gypsum) .
- a pH reducing component can be added to the inventive composition to increase its injectability.
- a pH reducing component is for example ascorbic acid or citric acid.
- These acids are included in a sterile liquid or a sterile powder of the composition in amounts of 0.1-5 wt%, preferably 0.5-2 wt% .
- Another way to further improve the injectability of the composition is to add a biologically compatible oil.
- the concentration of the oil should in this case be between 0.01 and 5 wt%, preferably between 0.1 and 2 wt%.
- the oil can either be intermixed with the sterile powder or included in the sterile aqueous liquid of the composition.
- a suitable oil to be used in the inventive composition is vitamin E.
- the vitamin E is ⁇ -tocopherol .
- the particulate hardened calcium sulfate can comprise at least one additive that is slowly released from the bone mineral substitute material after it has set.
- the additive can both be non-water soluble and water soluble.
- An example of a non-water soluble additive is vitamin E.
- the additive is water soluble.
- the water soluble additive can have several functions. It can for example be an antioxidant, a vitamin, a hormone, an antibiotic, a cytostatic, a bisphosphonate, a growth factor, or a protein.
- the at least one water soluble additive is a substance that induces, stimulates and/or accelerates bone formation, such as osteoinductive compounds and/or compounds reducing bone turn over .
- Suitable bone inducing substances which stimulate and/or accelerate bone formation, are growth factors and hormones. Growth factors and derivatives thereof are preferred, which are locally acting.
- growth factors which are autologous and effective in connection with bone, tendon or cartilage.
- growth factors are for example transforming growth factor (TGF ⁇ 3), bone morphogenic protein (BMP-2), PTHrP, osteoprotegrin (OPG) , Indian Hedgehog, RANKL, basic fibroblast, insulin-like growth factor (IgFl), platelet derived growth factors, and vascular growth factors.
- TGF ⁇ 3 transforming growth factor
- BMP-2 bone morphogenic protein
- PTHrP bone morphogenic protein
- osteoprotegrin OPG
- Indian Hedgehog hepatocyte growth factor
- RANKL basic fibroblast
- IgFl insulin-like growth factor
- platelet derived growth factors platelet derived growth factors
- vascular growth factors vascular growth factors.
- endogenously produced growth factors are used as an additive either as single entities or combined in a growth factor mixture in order to accelerate bone growth.
- an endogenously produced bioactive molecule is used as a substance that induces bone formation
- bone stimulating compounds are parathyorid hormones and derivatives thereof, estrogenes, progesterones, androgenes, testosterones, calcitonin, somatomedin, and oxytocin, preferably also autologous, but they can also be produced according to procedures known within the art.
- the enamel matrix proteins amelin-1, amelin-2 and ameloblastin can also be included as an additive in the particulate calcium sulfate, which are either autologous or extracted from or produced by tissues or cells from other species, or synthetically produced or produced by other living cells or organisms.
- the cholesterol-lowering compound statin can also be included in order to induce, stimulate and/or accelerate bone formation.
- suitable bone breakdown inhibitors are biphosphonates, osteocalcin, osteonectin and derivatives thereof, which can be included as an additive in the particulate calcium sulfate of the inventive composition and of the resulting substitute.
- other substances that influence the metabolism of bone may also be included in the particulate hardened calcium sulfate component to be slowly released from the resulting artificial bone mineral substitute material.
- Such substances include calciferols, calcitriols, as well as other D vitamins and derivatives thereof. These compounds help to regulate calcium metabolism and the normal calcification of bones in the body as well as influence the utilization of mineral phosphorus.
- prostaglandins Natural or synthetically produced prostaglandins, precursors or meta- bolites to prostaglandins, prostaglandin analogues or compounds that induce or inhibit endogenous prostaglandin production or induce or inhibit prostaglandin metabolism, or compounds that affect the production of precursors or further metabolism of active prostaglandin metabolites, may also be included.
- Analgesics such as lidocaine-HCl, bupivacaine-HCl, and ketorolac tromethamine, can also be used as an additive to be liberated from the bone mineral substitute material.
- Such additives should preferably be released from the bone mineral substitute material within 6-8 weeks after injection. This can be accomplished by controlling the dissolution of the particulate calcium sulfate in the bone mineral substitute material, the dissolution rate being dependent on the size and the form of the calcium sulfate particles .
- the water soluble additive can also be an anti- infectious substance, i.e. a compound with a static or cidal effect against invading foreign living material.
- anti- infectious substance i.e. a compound with a static or cidal effect against invading foreign living material.
- Such compounds include natural antibiotics as well as other semisynthetic and synthetic antibacterial or bacteriostatic compounds, which are acting against pathogenic and/or infectious microorganisms, e.g. staphylococci .
- antibiotics for bone infections are tetracycline-HCl, vancomycin, tobramycin, gentamycin, and cephalosporin .
- Cytostatic agents such as cis-platinum, ifosfamide, methotrexate, doxorubicin-HCl, arsenic trioxide, and retinoids or derivatives thereof can also be used as an additive.
- the additive can in a similar way be an antiviral compound, an antifungal compound, a tuberculostatic or tuberculocidal compound or an antiparasite compound.
- the water soluble additive which may be included in the particulate calcium sulfate, can also be a non-ionic X- ray contrast agent.
- Suitable such agents are conventional water soluble non-ionic X-ray contrast agents, i.e. iodinated aromatic compounds, which have one or several aromatic nuclei that are at least triiodo-substituted.
- Such agents are shown in US 5,695,742 and comprise CAS (Chemical Abstract Service) registration numbers 31112-62-6 (metrizamide) , 60166-93-0 (iopamidol) , 78649-41-9 (iomeprol) , 73334-07-3 (iopromide) , 877771-40-2 (ioversol) , 66108-95-0 (iohexol) , 89797-00-2 (iopentol) , 107793-72-6 (ioxilan) , 99139-49-8 (II-l), 75751-89-2 (iogulamide) , 63941-73-1 (ioglucol) , 63941-74-2 (ioglucamide) , 56562-79-9 (i
- X-ray contrast agents are shown in US 5,447,711 and comprise iotrolan, ioxaglate, iodecimol, and iosarcol .
- suitable contrast agents are iotusal, ioxilane, and iofrotal .
- the X-ray contrast agent is non-ionic and has a low osmomolality, such as iohexol, iodixanol, ioversol, iopamidol, and iotrolane.
- iohexol (Ci 9 H 26 I 3 3 ⁇ 9 ) can with advantage be used as an X-ray contrast agent.
- This substance does not influence bone formation and it has a good biocompability in bone. It is used for different purposes in medicine. For example it can be used for patients with kidney failure to determine the rate of plasma clearance by the kidney.
- the inventive composition with a non-ionic X-ray contrast agent as a water soluble additive included in the particulate calcium sulfate can in itself be used as an X- ray contrast medium.
- An additive X-ray effect is obtained by means of the composition according to the invention, since the X-ray contrast ability of its ceramic component is utilized.
- the inclusion of at least one water soluble non-ionic X-ray contrast agent in the composition increases the original X-ray density of the X-ray dense bone substitute.
- no further ceramic radio contrast agents such as barium sulfate and zirconium dioxide, have to be included in the injectable composition according to the invention.
- Such hard ceramic particles will wear joints when torn off from the bone substitute. In the joints they will cause physical damage and eventually result in in- fla matory reactions .
- the inventive composition when it .comprises a water soluble non-ionic X-ray contrast agent, can be injected adjacent to joints, and the resulting artificial bone mineral substitute material can be used for bone defects communicating with joints.
- Such applications include the repair of osteochondral joints defects as well as fractures or bone defects involving a joint.
- the dual origin of X-ray density can be further exploited, for example in order to localize the injected composition and to follow the healing process after implantation of the inventive composition in a human or animal body.
- the obtained artificial bone mineral substitute material which comprises a water soluble non- ionic X-ray contrast agent
- the water soluble agent will slowly disappear. This results in a progressive decline in X-ray density, which can be monitored.
- the particulate hardened calcium sulfate is according to the invention mixed with the powdered calcium phosphate component, which is subsequently hardened to a calcium phosphate cement in the bone mineral substitute material.
- calcium phosphate cement refers to the recognized definition (S. E. Gruninger, C. Siew, L. C Chow, A. O'Young, N. K. Tsao, W. E. Brown, J. Dent . Res . 63 (1984) 200) of a reaction product of a powder or a mixture of powders which - after mixing with water or an aqueous solution to a paste - at a temperature around room temperature or body temperature react with the formation of a precipitate, which contains crystals of one or more calcium phosphates and which sets by the entanglement of the crystals within the precipitate.
- different calcium phosphate products can be obtained during the setting reaction in dependence on the component (s) of the powdered calcium phosphate used for the paste in the inventive injectable composition for a bone mineral substitute material.
- the at least one calcium phosphate component is a powdered calcium phosphate with the capability of being hardened (cemented) to a calcium phosphate cement when reacting with the aqueous liquid under the influence of the at least one accelerator.
- the aqueous liquid should comprise between 0.1 and 2 ml, preferably between 0.2 and 0.7 ml per gram of the dry mixture.
- the aqueous liquid may be provided in an amount that is sufficient for this hardening reaction only.
- the aqueous liquid can be distilled water and/or a solution comprising one or several inorganic and/or organic salts .
- the main requirement on an injectable composition for a bone mineral substitute material is fulfilled, i.e. it should have a viscosity so that it can be injected into a bone for 1-5 minutes after the beginning of the mixing procedure.
- the initial setting time is within 5-25 minutes, which also is a prerequisite for an injectable composition.
- the at least one calcium phosphate component of injectable composition for a bone mineral substitute material is hardened to a hydroxyapatite (HA) .
- HA hydroxyapatite
- Those reactions, which form hydroxyapatite, i.e. precipitated hydroxyapatite (PHA) or calcium deficient hydroxyapatite (CDHA) can be classified into three groups.
- the first group consists of calcium phosphates, which are transformed into hydroxyapatite by a hydrolysis process in an aqueous solution (eq. 1-5) .
- Precipitated hydroxyapatite is the least soluble calcium phosphate at pH over 4,2. This means that any other calcium phosphate present in an aqueous solution at this pH range will tend to dissolve, with the precipitation of PHA as a product.
- This hydrolysis process (Ca(OH) 2 - H 3 PO 4 - H 2 0) is very slow due to a decrease in supersaturation as the reaction proceeds .
- the second group of reactions to a hydroxyapatite i.e. precipitated hydroxyapatite (PHA) or calcium deficient hydroxyapatite (CDHA)
- PHA precipitated hydroxyapatite
- CDHA calcium deficient hydroxyapatite
- TTCP is the only calcium phosphate with Ca/P-ratio above 1.67.
- this substance can be mixed with other calcium phosphates with lower Ca/P- ratio to obtain PHA or CDHA without the formation of acids or bases as by-products.
- any calcium phos- phate more acid than PHA can react directly with TTCP to form HA or CDHA according to the following chemical reactions .
- DCPD is formed as an intermediate reaction product, but with PHA or CDHA at the end of the reaction.
- Reactions (13), (14), and (15) are all very slow.
- by using the formulas (9) -(12) it is possible to produce a cement which sets and hardens with time at room or body temperature and at a neutral pH .
- PHA as the final hardened product by using mixtures of calcium phosphates with a Ca/P ratio of less than 1.67. This is accomplished by using additional calcium sources, such as Ca(OH) 2 or CaC0 3 , instead of TTCP.
- additional calcium sources such as Ca(OH) 2 or CaC0 3 , instead of TTCP.
- TTCP additional calcium sources
- One example is the reaction ⁇ -TCP + DCPD + CaC0 3 ⁇ PHA. Initially formed crystals of PHA from a reaction between DCPD and CaC0 3 function as binders between ⁇ - TCP particles. When DCPD is consumed the reaction continues between the remaining calcium carbonate and ⁇ -TCP with the formation of PHA. However, it seems that the latter process has a detrimental effect on the mechanical strength of the cement .
- the powdered at least one calcium phosphate component with the capability of being hardened to a calcium phosphate cement when reacting with an aqueous liquid is tetracalcium phosphate (TTCP) , mono- calcium phosphate monohydrate (MCPM) , dicalcium phosphate dihydrate (DCPD), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate (DCP) , tricalcium phosphate (TCP) , or octocalcium phosphate (OCP) .
- TTCP tetracalcium phosphate
- MCPM mono- calcium phosphate monohydrate
- DCPD dicalcium phosphate dihydrate
- DCPA dicalcium phosphate
- DCP dicalcium phosphate
- TCP tricalcium phosphate
- OCP octocalcium phosphate
- the calcium phosphate is ⁇ -tricalcium phosphate.
- the powdered at least one calcium phosphate component should comprises 40-98 wt%, preferably 60-90 wt of the dry mixture comprising the calcium phosphate component and the calcium sulfate component.
- the powdered calcium phosphate component has to be rapidly hardened with the restricted amount of available water in order to provide a bone substitute with acceptable properties within 15 min after injection.
- the hardening reaction of this component to a calcium phosphate cement can by means of the composition according to the invention be controlled to set within 18 h as a bone mineral substi- tute material with a strength of about 30 MPa.
- the water soluble additive is an accelerator for hardening the powdered calcium phosphate to a calcium phosphate cement when reacting with the aqueous liquid.
- an accelerator can be a phosphate salt, for example disodium hydrogen phosphate (Na 2 HP0 4 ) .
- the rate of the hardening reaction in vivo can be varied by varying the amount of phosphate salt between 0.01 and 10 wt% of the total composition, the salt being included in the particulate hardened calcium sulfate to be subsequently slowly released therefrom.
- the phosphate salt can also be dissolved in the aqueous liquid.
- the accelerator should be present in the aqueous liquid at concentrations of 0.1-10 wt%, preferably 1-5 wt% .
- the reaction of the powdered calcium phosphate component to a calcium phosphate cement can also be accelerated by adding hardened particulate calcium phosphate cement to the inventive composition as an accelerator.
- the hardened calcium phosphate cement can be hydroxyapatite (HA) , precipitated hydroxyapatite (PHA) , or preferably calcium deficient hydroxyapatite (CDHA) , or a mixture thereof. It should have a Ca/P ratio between 1.5 and 2.
- the particulate calcium phosphate cement as an accelerator should have a particle size which is less than 20 ⁇ m, preferably less than 10 ⁇ m and comprise between 0.1 and 10 wt%, preferably between 0.5 and 5 wt% of the calcium phosphate which is to react with an aqueous liquid.
- the hardening reaction can be adapted to last about 18 h in order to set to a high strength material.
- the already hardened sulfate will confer an initial strength to the implant, and when the setting reaction of calcium phosphate component to a high strength material is completed, a final strength will be obtained.
- the artificial bone mineral substitute material will retain its stability for 3-4 years. Each particle of calcium sulfate dihydrate will contain larger amounts of sulfate crystals. When the artificial bone mineral substitute material is resorbed in the body, the water in the blood will ultimately dissolve the crystals of the hardened sulfate ceramic and release any additive therein. It should be noted, that this reaction with several orders of magnitude is very much slower than the hardening reaction of the calcium phosphate component to a calcium phosphate cement.
- Additives which are bound to the sulfate crystals, will be released in vivo together with the calcium sulfate when the body fluid with time comes in contact with the bone mineral substitute material.
- the pore formation is accompanied by a controllable slow release of at least one additive in the hardened bone substitute, which has advantageous properties in vivo .
- Water soluble additives will be released and dissolved to effectively exert their effects at the site of action.
- pores, holes and cavities will gradually be formed as the sulfate degrades, which act like lacuna, and the finally set and hardened implant of a high strength material will look like a normal bone. Elongated particles are preferred. This results in that a contact can be obtained between the blood and a majority of the hardened calcium sulfate particles in the bone mineral substitute material, which are dissolved within 6-12 months.
- Particles as aggregates of single crystals can also be used in order to provide small distances between each crystal.
- Such particles of can be provided by particulate calcium sulfate hemihydrate.
- the ⁇ -form of calcium sulfate hemihydrate is preferred instead of the ⁇ - form, not only because of its increased mechanical strength but also because of its crystal size.
- the water soluble as well as the non-water soluble additive can be included in the particulate hardened calcium sulfate during its preparation.
- the water soluble additive at a suitable concentration in a aqueous solution is mixed with calcium sulfate hemihydrate, and the reaction with gypsum as product is allowed to take place:
- gypsum The structure of gypsum consists of layers of alternate S0 4 2 ⁇ ions strongly bonded to Ca 2+ and sheets of water molecules, and the additives will bind to the sulfate crystals of the particulate calcium sulfate.
- the water soluble additive is similarly included in the particulate calcium sulfate during its preparation.
- the gypsum is in this case ground and heated until about 75 % of the water has evaporated, and CaS0 4 " ⁇ H 2 ⁇ is obtained.
- the two known forms ( ⁇ and ⁇ ) of calcium sulfate hemihydrate are produced differently according to: heat 2 (CaS0 -2H 2 0) - 2 (CaS0 4 - ⁇ H 2 0) + 3H 2 0 (17)
- the ⁇ -form is obtained by dehydrating gypsum hydro- thermally in the presence of electrolytes.
- the ⁇ -form is produced by dehydrating gypsum in a water atmosphere at temperatures above 100°C. Accordingly, the water soluble additive at a suitable concentration in a aqueous solution is allowed to be present when these reactions take place.
- the water soluble additive will in a similar way adhere by means of electrostatic interactions with the residual crystal water of the particulate hardened calcium sulfate.
- a preferred way to produce the calcium sulfate hemihydrate is to utilize the already prepared particulate dihydrate having a water soluble additive included therein.
- the ground gypsum is subjected to the neces- sary heat treatment in for example an autoclave, crystals being produced which can be used as particulate calcium sulfate .
- water soluble additives have to be thermostable if included in the particulate calcium sulfate that is to be transformed into calcium sulfate hemihydrate .
- An efficient mixing system must be available in order to prepare the injectable composition according to the invention.
- the mixing can take place in a conventional cement mixing system and the composition is injected by means of a convenient delivery system.
- the mixing container is preferably of that type which can suck the aqueous component into the powder component (German Patent 4409610) .
- This PrepackTM system is a closed mixing system for delivery in combination with prepacked components in a flexible foil bag.
- Other mixing devices can of course also be used, for example two interconnected soft bags that can be adapted to a delivering cylinder.
- the formation of air bubbles in the composition can be prevented by mixing the inventive composition under conditions of subatmospheric pressure, e.g. in vacuo .
- subatmospheric pressure e.g. in vacuo
- an atmospheric pressure can also be used.
- the dry mixture of the composition is sterilized by means of radiation before it is mixed with the sterile aqueous liquid.
- the hardened bone mineral substitute material can be prefabricated in a suitable shape, e.g. as pellets or balls containing at least one, which allows for the attachment of implants and/or treatment of diseases, etc.
- the water soluble additive is a bioactive agent.
- Hardened calcium sulfate is for example produced as massive blocks, which are processed, e.g. grinded, to particles having the specific size that is also suitable for bone ingrowth. The shape of these blocks is of no consequence for the invention.
- the invention also concerns a bone mineral substitute material produced from the composition according to the invention. Such an implant can be introduced into an animal or human body after it has been hardened.
- the inventive composition, or the bone mineral sub- stitute material itself can be used in a wide variety of applications, such as fracture healing, prosthetic implants, and implants of foreign materials in other situations.
- Such situations may comprise filling a gap or a bone void or a pre-existing bone cavity, such as fractures, osteotomy, for the attachment of prostheses or other foreign material, for prosthetic revision surgery, for plastic surgery, for reconstruction surgery, or for cosmetic surgery.
- compositions as well as the bone mineral substitute material are suitable for local use in tooth pockets and/or bifurcatures to treat periodontitis or to be combined with other treatment options for periodontitis included therein, such as supportive matrix proteins or locally acting growth inducing factors .
- they can be used together with collagen or other supports, which are of importance for the growth of supportive tissues.
- the injectable composition is also mouldable and can thus be used for the filling of maxillar, frontal, ethmoidal, or spheroidal sinuses to allow attachment of screws, needles etc., such as the attachment of tooth implants with a pin or a screw or a needle up through the maxillar sinus .
- the injectable composition can be used to fill skeletal defects caused by the removal of orthopedic screws, pins or needles, which are utilized for internal or external fixation of fractures. It is in such occasions preferred that antibiotics are included in the composition as additives.
- the injectable composition can also be used together with expanders to create room for a material to be inserted, such as an inflatable balloon or a metal expander that is removed before the introduction of the composition or an expander filled with the composition, or a stent filled with the composition or attached to the bone mineral substitute material.
- the invention also concerns a method of implanting a bone substitute to a supportive tissue in a human or non-human animal subject, wherein an injectable composition for a bone mineral substitute material is introduced into said tissue, said injectable composition having the capability of being hardened in a body fluid in vivo and comprises an aqueous liquid; at least one calcium sulfate component of particulate calcium sulfate; and at least one calcium phosphate component of powdered calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with said aqueous liquid under the influence of at least one accelerator, said aqueous liquid being provided in an amount that is sufficient for said hardening reaction only; said at least one calcium phosphate component and said at least one calcium sulfate component being provided as a dry mixture.
- Instrumental or non-instrumental non-invasive or invasive fusion surgery can be performed when utilizing the inventive composition or the bone mineral substitute material itself, for example in connection with the spine or joints, such as finger joints, vertebral joints, shoulder joints, etc.
- Another embodiment of the invention which can be used in connection with the above-mentioned applications, comprises local injection of the composition with a con- comitant systemic treatment with a bioactive agent.
- a systemic treatment can be given as single or sustained treatments .
- Suitable bioactive agents are the above- mentioned water soluble additives that induce, stimulate and/or accelerate bone formation, or inhibit bone degrada- tion, e.g. bone inducing agents, such as parathyroid hormones, growth factors or statins.
- a systemic treatment can be applied with agents that inhibit bone metabolism, such as biphosphonates .
- the invention also concerns a method of prophylactic or therapeutic treatment of a disorder related to supportive tissues in a human or non-human animal subject, which method comprises providing to said subject a composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo, which comprises an aqueous liquid; at least one calcium sulfate component of particulate calcium sulfate; and at least one calcium phosphate component of powdered calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with said aqueous liquid under the influence of at least one accelerator, said aqueous liquid being provided in an amount that is sufficient for said hardening reaction only; said at least one calcium phosphate component and said at least one calcium sulfate component being provided as a dry mixture; while systemically and concomitantly administrating a prophylactic or therapeutic amount of at least one bioactive agent.
- a composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo
- a preferred embodiment of the invention comprises a corresponding local treatment or prophylaxis of a disorder, the injectable composition comprising bioactive agents.
- This embodiment involves a method of prophylactic or therapeutic treatment of a disorder related to supportive tissues in a human or non-human animal subject, which method comprises providing to said subject a composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo, which comprises an aqueous liquid; at least one calcium sulfate component of particulate calcium sulfate; and at least one calcium phosphate component of powdered calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with said aqueous liquid under the influence of at least one accelerator, said aqueous liquid being provided in an amount that is sufficient for said hardening reaction only; said at least one calcium phosphate component and said at least one calcium sulfate component being provided as a dry mixture; while concomitantly administrating a prophylactic or therapeutic amount of at least
- the method is especially useful for local treatment of infections or infestations in the musculoskeletal system, such as osteomyelitis caused by e.g. bacteria.
- a combined supportive or osteoconductive treatment and a prophylaxis of skeletal infection can thus be obtained, e.g. in sternotomies, prosthetic implants, reconstructive surgery, trauma surgery, cancer surgery, cosmetic surgery, and oro-maxillar surgery.
- This method is also useful for local treatment with cytostatic agents, such as in musculoskeletal tumors, e.g. metastases in vertebrae from breast or prostatic cancers demanding treatment with a supportive material that concomitantly gives a possibility for local treatment with tumor- inhibiting agents.
- it can be used locally together with agents that enhances the clinical effects of irradiation in diseases, such as tumor diseases.
- This method can also be used for local and supportive treatment with agents that inhibit bone resorption or stimulate bone formation.
- Example 1 Slow release of an X-ray contrast agent .
- a composition according to the invention was prepared, which contained 40 wt% hydroxyapatite and 60 wt% particulate hardened calcium sulfate, which had been previously doped with 5 wt% of the non-ionic X-ray contrast agent iohexol (12.1 g iohexol/100 g particles).
- the release from day 1 is the total release during that day. In total, more than 94 % of the doped agent was released.
- compositions according to the invention was prepared, which contained 80 wt% hydroxyapatite and 20 wt% particulate hardened calcium sulfate, which had been previously doped with two different concentrations (3 and 6 wt%) of the antibiotic gentamicin sulfate.
- the release of gentamicin from the calcium sulfate based material in an isotonic buffer was followed in vi tro .
- the results are shown in FIG 2.
- the release was faster with 6 wt% (D) than with 3 wt% ( * ) gentamicin.
- a composition according to the invention was prepared, which had a particle size distribution of less than 100 ⁇ m.
- the composition was successfully injected into narrow piglet trabecular bone channels as well as into spine of human cadaver and set in situ . Microphotographs reveal that the composition has entered and penetrated the microchannels of bone, which have a size of 200-300 ⁇ m or less.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Composite Materials (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL04717912T PL1601387T3 (en) | 2003-03-05 | 2004-03-05 | A new bone substitute composition |
JP2006507949A JP4805812B2 (en) | 2003-03-05 | 2004-03-05 | New bone substitute composition |
CA2518104A CA2518104C (en) | 2003-03-05 | 2004-03-05 | Artificial bone mineral substitute for in vivo hardening |
EP04717912A EP1601387B1 (en) | 2003-03-05 | 2004-03-05 | A new bone substitute composition |
AU2004218550A AU2004218550B2 (en) | 2003-03-05 | 2004-03-05 | A new bone substitute composition |
CNB2004800097919A CN100536932C (en) | 2003-03-05 | 2004-03-05 | A new bone substitute composition |
DE602004022024T DE602004022024D1 (en) | 2003-03-05 | 2004-03-05 | NEW BONE REPLACEMENT COMPOSITION |
US10/547,671 US8420127B2 (en) | 2003-03-05 | 2004-03-05 | Bone substitute composition |
HK05111471.0A HK1079464A1 (en) | 2003-03-05 | 2005-12-14 | A new bone substitute composition |
US13/799,959 US20130268088A1 (en) | 2003-03-05 | 2013-03-13 | Bone substitute composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300620A SE0300620D0 (en) | 2003-03-05 | 2003-03-05 | A new bone substitute composition |
SE0300620-2 | 2003-03-05 | ||
US45554903P | 2003-03-19 | 2003-03-19 | |
US60/455,549 | 2003-03-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/799,959 Continuation US20130268088A1 (en) | 2003-03-05 | 2013-03-13 | Bone substitute composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004078223A1 true WO2004078223A1 (en) | 2004-09-16 |
Family
ID=20290603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2004/000328 WO2004078223A1 (en) | 2003-03-05 | 2004-03-05 | A new bone substitute composition |
Country Status (13)
Country | Link |
---|---|
US (2) | US8420127B2 (en) |
EP (1) | EP1601387B1 (en) |
JP (1) | JP4805812B2 (en) |
CN (1) | CN100536932C (en) |
AU (1) | AU2004218550B2 (en) |
CA (1) | CA2518104C (en) |
DE (1) | DE602004022024D1 (en) |
ES (1) | ES2330108T3 (en) |
HK (1) | HK1079464A1 (en) |
PL (1) | PL1601387T3 (en) |
PT (1) | PT1601387E (en) |
SE (1) | SE0300620D0 (en) |
WO (1) | WO2004078223A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009538162A (en) * | 2006-05-26 | 2009-11-05 | バクスター・インターナショナル・インコーポレイテッド | Injectable bone void filler |
EP2139507A1 (en) * | 2007-04-27 | 2010-01-06 | Unigene Laboratories, Inc. | Methods and compositions for fostering and preserving bone growth |
CN102008748A (en) * | 2010-11-08 | 2011-04-13 | 胡钢锋 | Application of injectable degradable calcium sulfate and calcium phosphate material in repairing femoral head necrosis |
EP2353619A1 (en) | 2010-02-09 | 2011-08-10 | Bone Support AB | Preparation of Bone Cement Compositions |
US8586101B2 (en) | 2001-12-20 | 2013-11-19 | Bone Support Ab | Bioresorbable bone mineral substitute comprising water-soluble X-ray contrast agent |
US8662737B2 (en) | 2004-06-22 | 2014-03-04 | Bone Support Ab | Device for producing a hardenable mass |
US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
EP2117612B1 (en) | 2007-02-14 | 2015-07-29 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
US9144631B2 (en) | 2003-01-27 | 2015-09-29 | Benedicte Asius | Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
WO2016007080A1 (en) * | 2014-07-10 | 2016-01-14 | Bone Support Ab | Injectable bone substitutes for augmenting implant fixation |
US9421302B2 (en) | 2006-05-26 | 2016-08-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
EP3071140A4 (en) * | 2013-11-21 | 2017-07-26 | The University of Toledo | Macroporous granules of alkaline earth phosphates using cement technology and gas evolving porogen |
CN107670102A (en) * | 2017-11-19 | 2018-02-09 | 赵亮 | A kind of bone Biocomposite material and preparation method and application for raising endogenous cell |
GB2559761A (en) * | 2017-02-16 | 2018-08-22 | Corthotec Ltd | Composition for improved bone fracture healing |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
WO2019206677A1 (en) * | 2018-04-23 | 2019-10-31 | Seagles Ab | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE520688C2 (en) * | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
SE517168C2 (en) * | 2000-07-17 | 2002-04-23 | Bone Support Ab | A composition for an injectable bone mineral replacement material |
SE0300620D0 (en) | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
SE0302983D0 (en) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Apparatus for providing spongy bone with bone replacement and / or bone strengthening material and associated method |
US20060089723A1 (en) * | 2004-10-25 | 2006-04-27 | Murphy Kieran P | Method for bone augmentation |
BRPI0617086B8 (en) | 2005-09-09 | 2021-06-22 | Agnovos Healtcare Llc | bone graft substitute composite cement and articles originated from it |
US20070077267A1 (en) * | 2005-10-03 | 2007-04-05 | Sdgi Holdings, Inc. | Bioactive composite implants |
EP2148708A4 (en) * | 2007-04-18 | 2012-12-05 | Univ Mcgill | Composition for enhancing bone formation |
EP2077126A1 (en) * | 2008-01-07 | 2009-07-08 | Graftys | Analgesic apatitic calcium-phosphate cement |
WO2009143236A1 (en) * | 2008-05-20 | 2009-11-26 | Albert Einstein Healthcare Network | Compositions and methods for the treatment of skeletal metastatic lesions and fractures |
DE102009001895A1 (en) * | 2009-03-26 | 2010-09-30 | Biotronik Vi Patent Ag | Medical implant for drug release with porous surface |
CA2784533C (en) * | 2009-12-18 | 2016-02-09 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
TW201121591A (en) * | 2009-12-29 | 2011-07-01 | Far Eastern New Century Corp | Porous bone cement |
WO2012057836A2 (en) | 2010-10-26 | 2012-05-03 | Cap Biomaterials, Llc | Composites of hydroxyapatite and calcium carbonate and related methods of preparation and use |
ES2714701T3 (en) | 2010-11-10 | 2019-05-29 | Stryker European Holdings I Llc | Process for the preparation of a polymeric bone foam |
US20120195982A1 (en) * | 2011-01-28 | 2012-08-02 | Beijing Allgens Medical Science & Technology Co., Ltd. | Injectible, biocompatible synthetic bone growth composition |
DK2793915T3 (en) | 2011-12-23 | 2020-03-09 | Cerapedics Inc | IMPLANTABLE MATERIALS FOR BONE REPAIR |
TWI414327B (en) * | 2012-08-28 | 2013-11-11 | Far Eastern Memorial Hospital | Complex bone cement |
CA2905111A1 (en) * | 2013-03-14 | 2014-09-25 | Skeletal Kinetics, Llc | Calcium phosphate cement compositions that set into high strength porous structures |
JP6316296B2 (en) * | 2013-08-06 | 2018-04-25 | クラレノリタケデンタル株式会社 | Hardening calcium phosphate composition for bone tissue repair, bone repair material and various dental materials |
TWI651103B (en) | 2013-12-13 | 2019-02-21 | 萊特醫技股份有限公司 | Multiphase bone graft replacement material |
US20150250610A1 (en) * | 2014-03-04 | 2015-09-10 | DePuy Synthes Products, LLC | Post-Operative Bone Grown Stimulant Introduction Method |
US9487443B2 (en) * | 2014-03-14 | 2016-11-08 | Ricoh Company, Ltd. | Layer stack formation powder material, powder layer stack formation hardening liquid, layer stack formation material set, and layer stack object formation method |
AU2016236326A1 (en) * | 2015-03-23 | 2017-10-12 | Bone Support Ab | Biphasic ceramic bone substitute |
CN106518048A (en) * | 2015-03-31 | 2017-03-22 | 蒋超 | High biological activity substitute bioceramic for bone repair |
RU2614360C1 (en) * | 2016-02-24 | 2017-03-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Treatment method of haematogeneous osteomyelitis of vertebral column |
US10471176B2 (en) | 2017-03-14 | 2019-11-12 | National Taiwan University | Composition material and method for free forming bone substitute |
US11235086B2 (en) | 2018-02-22 | 2022-02-01 | Cerapedics, Inc. | Processes for coating inorganic particles with a peptide or protein useful for improving cellular activity related to bone growth |
US11529438B2 (en) * | 2018-06-25 | 2022-12-20 | Bioventus, Llc | Porous carrier matrix |
CN110755680B (en) * | 2019-11-25 | 2022-05-17 | 中鼎凯瑞科技成都有限公司 | Vitamin D-loaded calcium citrate/calcium sulfate composite bone cement and preparation method thereof |
EP4335466A1 (en) * | 2022-09-08 | 2024-03-13 | Heraeus Medical GmbH | Composition for the preparation of a bone substitute material, method for the preparation of a pharmaceutical active substance carrier, pharmaceutical active substance carrier and its use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0639382A1 (en) * | 1993-08-18 | 1995-02-22 | Mit Pharmaca Ab | Cement for medical use, method for producing the cement, and use of the cement |
WO2002005861A1 (en) * | 2000-07-17 | 2002-01-24 | Bone Support Ab | A composition for an injectable bone mineral substitute material |
WO2003041753A1 (en) * | 2001-11-14 | 2003-05-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pasty or liquid multiple constituent compositions for injectable calcium phosphate cements |
WO2003053488A1 (en) * | 2001-12-20 | 2003-07-03 | Bone Support Ab | A new bone mineral substitute |
WO2004000374A1 (en) * | 2002-06-19 | 2003-12-31 | Dr. H.C. Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US949163A (en) * | 1909-07-07 | 1910-02-15 | Bridgeport Brass Co | Grease-gun. |
US1644173A (en) | 1923-02-01 | 1927-10-04 | Bassick Mfg Co | Lubricating apparatus |
US1865912A (en) * | 1930-03-25 | 1932-07-05 | Horn William | Oil well agitator |
US2545017A (en) * | 1947-06-02 | 1951-03-13 | Gordon D Billingsley | Hypodermic syringe |
US3367783A (en) * | 1966-03-23 | 1968-02-06 | Gerber Prod | Process of preparing a fruit gel |
US3475010A (en) | 1968-04-24 | 1969-10-28 | Prod Res & Chem Corp | Dispensing cartridge for intermixing separate ingredients |
US3688765A (en) * | 1969-10-03 | 1972-09-05 | Jack S Gasaway | Hypodermic injection device |
US3837379A (en) * | 1973-05-14 | 1974-09-24 | East West Med Prod | Irrigator liquid supply system |
CH608189A5 (en) * | 1974-12-13 | 1978-12-29 | Savac Ag | |
US3965910A (en) * | 1975-04-28 | 1976-06-29 | Walpak Company | Urinary irrigation valve |
CH626873A5 (en) * | 1977-03-28 | 1981-12-15 | Bracco Ind Chimica Spa | |
US4240425A (en) | 1978-10-23 | 1980-12-23 | American Hospital Supply Corporation | Syringe with plug type needle hub lock |
IT1207226B (en) * | 1979-08-09 | 1989-05-17 | Bracco Ind Chimica Spa | 2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM. |
US4338925A (en) * | 1979-12-20 | 1982-07-13 | Jo Miller | Pressure injection of bone cement apparatus and method |
US4269331A (en) * | 1980-02-15 | 1981-05-26 | Watson John D | Metered dispensing device |
US4496342A (en) * | 1981-03-20 | 1985-01-29 | Surgical Design Corporation | Surge prevention system for an ophthalmic instrument |
DE3206911A1 (en) | 1982-02-26 | 1983-09-15 | Lohmann Tierernährung GmbH, 2190 Cuxhaven | BIOCHEMICAL ACTIVE SUBSTANCE, THE PRODUCTION THEREOF AND SUBSTANCE CONTAINING THIS ACTIVE SUBSTANCE |
US4439420A (en) | 1982-11-16 | 1984-03-27 | Ethicon, Inc. | Absorbable hemostatic composition |
US4619655A (en) | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
US4583974A (en) * | 1984-04-04 | 1986-04-22 | Kokernak Denis T | Syringe for balloon dilation catheters |
DK350584A (en) * | 1984-07-18 | 1986-01-19 | Arne Bent Sjoegren | MIXING PUMP FOR EFFECTIVE MIXING (HOMOGENIZATION) OF TWO OR MORE LIQUIDS (AIR SPECIES) WITH A CONSTANT, BUT REGULAR, MIXING CONDITIONS |
SE450545B (en) * | 1984-10-19 | 1987-07-06 | Mit Ab | PROCEDURE AND DEVICE FOR MANUFACTURING BENCEMENT FOR FIXING PROSTHESIS |
GB8516344D0 (en) * | 1985-06-28 | 1985-07-31 | Brunold C R | Mixing apparatus & processes |
US4676655A (en) * | 1985-11-18 | 1987-06-30 | Isidore Handler | Plunger type cartridge mixer for fluent materials |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
ATE124235T1 (en) * | 1987-02-20 | 1995-07-15 | Draenert Klaus | SUCTION DRAINAGE BONE SCREW. |
ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
DE3731542A1 (en) | 1987-09-17 | 1989-03-30 | Schering Ag | NEW DICARBONIC ACID-BIS (3,5-DICARBAMOYL-2,4,6-TRIIOD-ANILIDE), METHOD FOR THE PRODUCTION THEREOF AND THESE CONTAINING X-RAY AGENTS |
US5605885A (en) * | 1988-05-05 | 1997-02-25 | Entremed, Inc. | Method for stimulating the immune system |
GB8919929D0 (en) * | 1989-09-04 | 1989-10-18 | Nycomed As | Compositions |
SE464912B (en) | 1989-10-25 | 1991-07-01 | Bioapatite Ab | Implantation material for re-establishing bone tissue and method for its production |
US5236456A (en) | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
IT1236864B (en) | 1989-12-29 | 1993-04-22 | Tecres Spa | PROCEDURE FOR MIXING AND ADMINISTRATING A TWO-PART BONE CONCRETE DIRECTLY ON THE SPOT, AND DEVICE THAT REALIZES IT |
US5071040A (en) | 1990-03-09 | 1991-12-10 | Pfizer Hospital Products Group, Inc. | Surgical adhesives mixing and dispensing implement |
US5168757A (en) | 1990-05-15 | 1992-12-08 | Ryder International Corporation | Fluid displacement and pressurizing device |
US5269785A (en) | 1990-06-28 | 1993-12-14 | Bonutti Peter M | Apparatus and method for tissue removal |
US5990382A (en) * | 1990-08-29 | 1999-11-23 | Biomedical Enterprises, Inc. | Method and implant for surgical manipulation of bone |
US6080801A (en) * | 1990-09-13 | 2000-06-27 | Klaus Draenert | Multi-component material and process for its preparation |
US5149368A (en) * | 1991-01-10 | 1992-09-22 | Liu Sung Tsuen | Resorbable bioactive calcium phosphate cement |
US5262166A (en) | 1991-04-17 | 1993-11-16 | Lty Medical Inc | Resorbable bioactive phosphate containing cements |
US5462722A (en) | 1991-04-17 | 1995-10-31 | Liu; Sung-Tsuen | Calcium phosphate calcium sulfate composite implant material |
US5232024A (en) * | 1991-05-30 | 1993-08-03 | Eli Williams | Slide-valve manifold |
DE4121043A1 (en) * | 1991-06-26 | 1993-01-07 | Merck Patent Gmbh | BONE REPLACEMENT MATERIAL WITH FGF |
DE69205736T2 (en) | 1991-06-26 | 1996-06-13 | Nitta Gelatin Kk | Hardenable calcium phosphate-containing material for repairing living hard tissues. |
US5281265A (en) * | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
SE510490C2 (en) * | 1992-02-07 | 1999-05-31 | Scandimed International Ab | Process for producing bone cement and apparatus for carrying out the process |
CA2103683C (en) * | 1992-08-17 | 1998-06-16 | George Weeks | Methods of controlling dust and compositions produced thereby |
IT1256248B (en) | 1992-12-24 | 1995-11-29 | Bracco Spa | WATER INJECTABLE FORMULATIONS FOR RADIODIAGNOSTICS INCLUDING MIXTURES OF IODURATED AROMATIC COMPOUNDS USEFUL AS X-RAY MATTING AGENTS |
US5403318A (en) * | 1993-01-15 | 1995-04-04 | Boehringer Laboratories, Inc. | Apparatus and method for shaping bone |
US5665066A (en) * | 1993-09-03 | 1997-09-09 | Ultradent Products, Inc. | Methods and apparatus for mixing and dispensing multi-part compositions |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
US5360823A (en) | 1993-11-02 | 1994-11-01 | Dawe's Inc. | Anionic salt formulation for milk fever |
EP0657208A1 (en) | 1993-12-08 | 1995-06-14 | Allo Pro Ag | Device for mixing a multicomponent cement and process for performing the mixing |
US6248110B1 (en) * | 1994-01-26 | 2001-06-19 | Kyphon, Inc. | Systems and methods for treating fractured or diseased bone using expandable bodies |
US6716216B1 (en) * | 1998-08-14 | 2004-04-06 | Kyphon Inc. | Systems and methods for treating vertebral bodies |
DE4409610C3 (en) | 1994-03-21 | 2001-09-20 | Scandimed Internat Ab Sjoebo | Mixing device |
DE4425218A1 (en) * | 1994-07-16 | 1996-01-18 | Merck Patent Gmbh | Device for mixing and discharging bone cement |
US6075067A (en) * | 1994-08-15 | 2000-06-13 | Corpipharm Gmbh & Co | Cement for medical use, method for producing the cement, and use of the cement |
DE4433201A1 (en) * | 1994-09-17 | 1996-03-21 | Merck Patent Gmbh | Process for the production of active ingredient-containing bone cements |
DE4435680A1 (en) * | 1994-10-06 | 1996-04-11 | Merck Patent Gmbh | Porous bone substitute materials |
US5616120A (en) * | 1995-02-06 | 1997-04-01 | Andrew; Mark S. | Method and apparatus for lenticular liquefaction and aspiration |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
ATE223734T1 (en) * | 1995-12-19 | 2002-09-15 | Bracco Research Sa | COMPOSITIONS CONTAINING TRICODOBENZENE POLYMERS FOR IMAGING THE GASTROINTESTINAL TRACT |
US6596904B1 (en) * | 1996-01-29 | 2003-07-22 | Mallinc Krodt Inc | Process for producing ioversol |
US6299905B1 (en) | 1996-04-16 | 2001-10-09 | Depuy Orthopaedics, Inc. | Bioerodable polymeric adhesives for tissue repair |
DE19620117C1 (en) | 1996-05-18 | 1997-07-24 | Corimed Kundenorientierte Medi | Preparation of medicinal composition containing calcium sulphate |
FR2749756B1 (en) * | 1996-06-14 | 1998-09-11 | Bioland | PROCESS FOR THE PREPARATION OF AN IMPLANTABLE COMPOSITE MATERIAL, MATERIAL OBTAINED, IMPLANT COMPRISING SUCH MATERIAL, AND IMPLEMENTATION KIT |
US5871549A (en) * | 1996-12-12 | 1999-02-16 | Johnson & Johnson Professional, Inc. | Femoral stem with reduced coefficient of friction with respect to bone cement |
US20020076378A1 (en) * | 1997-01-29 | 2002-06-20 | Nycomed Imaging As | Polymers |
US5842786A (en) | 1997-03-07 | 1998-12-01 | Solomon; Alan | Method and device for mixing medical compositions |
US5829875A (en) | 1997-04-02 | 1998-11-03 | Simpson Strong-Tie Co., Inc. | Combined barrier and mixer assembly for a cylindrical container |
US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
DE19718648A1 (en) | 1997-05-02 | 1998-11-05 | Merck Patent Gmbh | Method and device for producing sterile packed bone cement |
IT1292037B1 (en) | 1997-05-30 | 1999-01-25 | Bracco Spa | PROCESS FOR THE PREPARATION OF 5- (ACETYL 62,3-DIIDROXYPROPYL) - AMINO) -N, N'-BIS (2,3-DIIDROXYPROPYL) -2,4,6-TRIIODE-1,3-BENZEN- |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US6048346A (en) * | 1997-08-13 | 2000-04-11 | Kyphon Inc. | Systems and methods for injecting flowable materials into bones |
US6309420B1 (en) * | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
JP4145490B2 (en) | 1997-10-20 | 2008-09-03 | ピーアールシー−デソト インターナショナル,インコーポレイティド | Manual dispensing syringe for multi-component substances |
US6062722A (en) * | 1997-10-21 | 2000-05-16 | Micron Communications, Inc. | Fluid mixing and withdrawing methods |
US6440138B1 (en) * | 1998-04-06 | 2002-08-27 | Kyphon Inc. | Structures and methods for creating cavities in interior body regions |
DE19816858A1 (en) | 1998-04-16 | 1999-10-21 | Merck Patent Gmbh | Tricalcium phosphate-containing bio-cement pastes with cohesion promoters |
DE19817762A1 (en) | 1998-04-21 | 1999-10-28 | Dietmar Enk | Appts for intravasal blood measurement |
SE9801901L (en) * | 1998-05-29 | 1999-08-02 | Bone Support Ab | Process for producing powder component for cement for medical use, use of such powder component and such powder component |
GB2338428A (en) | 1998-06-19 | 1999-12-22 | David Grant | A syringe with an agitator whose shaft passes through a slidable dispensing plunger |
WO2000007639A1 (en) * | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
DE19853832A1 (en) | 1998-11-21 | 2000-05-25 | Merck Patent Gmbh | Calcium phosphate cements containing polyalkenoic acids |
US6120174A (en) * | 1999-01-14 | 2000-09-19 | Bristol-Myers Squibb | Apparatus and method for mixing and dispensing bone cement |
US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
JP2001106638A (en) | 1999-08-05 | 2001-04-17 | Takeda Chem Ind Ltd | Sustained release paste containing bone formation promoting substance |
EP1208850A1 (en) | 1999-08-05 | 2002-05-29 | Takeda Chemical Industries, Ltd. | Pastes with the sustained release of osteogenesis promoter |
DE19938704C1 (en) | 1999-08-14 | 2001-10-31 | Ivoclar Vivadent Ag | Process for the production of reaction systems for implantation in the human and animal body as a bone substitute, which i.a. Contain calcium and phosphorus |
JP2001104324A (en) * | 1999-10-06 | 2001-04-17 | Ngk Spark Plug Co Ltd | Medicine extruding auxiliary device, and medicine extruding method using the same |
DE19953771C1 (en) * | 1999-11-09 | 2001-06-13 | Coripharm Medizinprodukte Gmbh | Absorbable bone implant material and method for producing the same |
EP1155704A1 (en) | 2000-01-13 | 2001-11-21 | Chih-I Lin | Orthopedic filling material and method of use thereof |
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6790210B1 (en) * | 2000-02-16 | 2004-09-14 | Trans1, Inc. | Methods and apparatus for forming curved axial bores through spinal vertebrae |
US6723334B1 (en) * | 2000-03-01 | 2004-04-20 | Iowa State University Research Foundation, Inc. | Biologically compatible bone cements and orthopedic methods |
US6332894B1 (en) | 2000-03-07 | 2001-12-25 | Zimmer, Inc. | Polymer filled spinal fusion cage |
US6652883B2 (en) | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
SE520688C2 (en) * | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
ES2178556B1 (en) | 2000-06-30 | 2004-07-16 | Universitat Politecnica De Catalunya | CEMENT OF CALCIUM SULPHATE WITH CONTROLLED BIODEGRADATION. |
JP2002058736A (en) | 2000-08-17 | 2002-02-26 | Seikagaku Kogyo Co Ltd | Composition, medical instrument and kit for bone implantation |
JP2004533276A (en) | 2001-01-25 | 2004-11-04 | リジェネレーション テクノロジーズ インク. | Injectable porous bone graft material |
US7008433B2 (en) | 2001-02-15 | 2006-03-07 | Depuy Acromed, Inc. | Vertebroplasty injection device |
WO2002080933A1 (en) * | 2001-04-03 | 2002-10-17 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
ITMI20010773A1 (en) * | 2001-04-11 | 2002-10-11 | Chemi Spa | PROCESS FOR THE PRODUCTION OF HIGH PURITY IOEXOLO |
JP2002325831A (en) | 2001-05-02 | 2002-11-12 | Asahi Optical Co Ltd | Filling material for organism and manufacture thereof |
GB0110726D0 (en) * | 2001-05-02 | 2001-06-27 | Biocomposites Ltd | Bone implant composition |
US20030055512A1 (en) * | 2001-05-21 | 2003-03-20 | Genin Francois Y. | Calcium based neutral and bioresorbable bone graft |
US6547432B2 (en) * | 2001-07-16 | 2003-04-15 | Stryker Instruments | Bone cement mixing and delivery device for injection and method thereof |
US20030028251A1 (en) * | 2001-07-30 | 2003-02-06 | Mathews Hallett H. | Methods and devices for interbody spinal stabilization |
US6706069B2 (en) * | 2001-09-13 | 2004-03-16 | J. Lee Berger | Spinal grooved director with built in balloon |
US7799833B2 (en) | 2001-11-01 | 2010-09-21 | Spine Wave, Inc. | System and method for the pretreatment of the endplates of an intervertebral disc |
JP4499327B2 (en) * | 2001-12-06 | 2010-07-07 | 松崎 浩巳 | Diameter expansion instrument and surgical instrument set |
SE522098C2 (en) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Artificial bone mineral substitute material useful as an X-ray contrast medium comprises ceramic and water soluble non-ionic X-ray contrast agent |
US6780191B2 (en) * | 2001-12-28 | 2004-08-24 | Yacmur Llc | Cannula system |
SE524714C2 (en) | 2002-06-28 | 2004-09-21 | Asept Medical Ab | Bone cement processor and applicator |
DE10242984B4 (en) | 2002-09-17 | 2010-09-23 | Sanatis Gmbh | Device for producing mixtures of two components |
US20050287071A1 (en) | 2002-12-03 | 2005-12-29 | Kyphon Inc. | Formulation for a cement preparation as bone substitute |
DE60307683T2 (en) * | 2003-02-13 | 2008-05-15 | Synthes Gmbh | INJECTABLE MIXTURE FOR THE REPLACEMENT OF BONE FABRICS IN SITU |
US6905485B2 (en) | 2003-02-19 | 2005-06-14 | Becton, Dickinson And Company | Medical device with needle safety shielding |
US7393493B2 (en) * | 2003-02-27 | 2008-07-01 | A Enterprises, Inc. | Crosslinkable polymeric materials and their applications |
SE0300620D0 (en) | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
US20040191897A1 (en) * | 2003-03-31 | 2004-09-30 | The Cleveland Clinic Foundation | Apparatus and method for harvesting bone marrow |
US20040267272A1 (en) * | 2003-05-12 | 2004-12-30 | Henniges Bruce D | Bone cement mixing and delivery system |
US20050015074A1 (en) * | 2003-07-17 | 2005-01-20 | Trombley Frederick W. | Medical connector, fluid delivery system, and method of use therefor |
US7306786B2 (en) * | 2003-07-28 | 2007-12-11 | Skeletal Kinetics, Llc | Calcium phosphate cements comprising a water-soluble contrast agent |
SE0302983D0 (en) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Apparatus for providing spongy bone with bone replacement and / or bone strengthening material and associated method |
US7524103B2 (en) * | 2003-11-18 | 2009-04-28 | Boston Scientific Scimed, Inc. | Apparatus for mixing and dispensing a multi-component bone cement |
WO2005053581A1 (en) * | 2003-12-01 | 2005-06-16 | Broockeville Corporation N.V. | A tow-component mixing and dispensing device |
CA2564687A1 (en) | 2004-04-27 | 2005-11-10 | Kyphon Inc. | Bone substitute compositions and method of use |
US20050257714A1 (en) | 2004-05-20 | 2005-11-24 | Constantz Brent R | Orthopedic cements comprising a barium apatite contrast agent |
SE527528C2 (en) * | 2004-06-22 | 2006-04-04 | Bone Support Ab | Apparatus for the preparation of curable pulp and use of the apparatus |
US7776073B2 (en) * | 2004-06-30 | 2010-08-17 | Depuy Spine, Inc. | In-situ formed posterolateral fusion system |
US20060036271A1 (en) * | 2004-07-29 | 2006-02-16 | X-Sten, Inc. | Spinal ligament modification devices |
SE528360C2 (en) | 2004-09-10 | 2006-10-24 | Doxa Ab | Resorbable ceramic compositions intended for medical implants |
US7717918B2 (en) * | 2004-12-06 | 2010-05-18 | Dfine, Inc. | Bone treatment systems and methods |
KR20090054463A (en) | 2006-09-07 | 2009-05-29 | 와이어쓰 | Bone cement mixing system and related methods |
US7666160B2 (en) * | 2006-12-29 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery device |
US20100249753A1 (en) | 2009-02-25 | 2010-09-30 | Gaisser David M | Vented syringe system and method for the containment, mixing and ejection of wetted particulate material |
-
2003
- 2003-03-05 SE SE0300620A patent/SE0300620D0/en unknown
-
2004
- 2004-03-05 CN CNB2004800097919A patent/CN100536932C/en not_active Expired - Fee Related
- 2004-03-05 DE DE602004022024T patent/DE602004022024D1/en not_active Expired - Lifetime
- 2004-03-05 AU AU2004218550A patent/AU2004218550B2/en not_active Ceased
- 2004-03-05 ES ES04717912T patent/ES2330108T3/en not_active Expired - Lifetime
- 2004-03-05 EP EP04717912A patent/EP1601387B1/en not_active Expired - Lifetime
- 2004-03-05 PT PT04717912T patent/PT1601387E/en unknown
- 2004-03-05 US US10/547,671 patent/US8420127B2/en not_active Expired - Fee Related
- 2004-03-05 WO PCT/SE2004/000328 patent/WO2004078223A1/en active Application Filing
- 2004-03-05 JP JP2006507949A patent/JP4805812B2/en not_active Expired - Fee Related
- 2004-03-05 CA CA2518104A patent/CA2518104C/en not_active Expired - Fee Related
- 2004-03-05 PL PL04717912T patent/PL1601387T3/en unknown
-
2005
- 2005-12-14 HK HK05111471.0A patent/HK1079464A1/en not_active IP Right Cessation
-
2013
- 2013-03-13 US US13/799,959 patent/US20130268088A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0639382A1 (en) * | 1993-08-18 | 1995-02-22 | Mit Pharmaca Ab | Cement for medical use, method for producing the cement, and use of the cement |
WO2002005861A1 (en) * | 2000-07-17 | 2002-01-24 | Bone Support Ab | A composition for an injectable bone mineral substitute material |
WO2003041753A1 (en) * | 2001-11-14 | 2003-05-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pasty or liquid multiple constituent compositions for injectable calcium phosphate cements |
WO2003053488A1 (en) * | 2001-12-20 | 2003-07-03 | Bone Support Ab | A new bone mineral substitute |
WO2004000374A1 (en) * | 2002-06-19 | 2003-12-31 | Dr. H.C. Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
Non-Patent Citations (4)
Title |
---|
BOHNER M. ET AL.: "Effects of sulfate ions on the in vitro properties of beta-TCP - MCPM - water mixtures. Preliminary in vivo results", CERAMIC TRANSACTIONS, vol. 48, 1995, pages 245 - 259, XP002949443 * |
BOHNER M.: "New hydraulic cements based on alpha-tricalcium phosphate-calcium sulfate dihydrate mixtures", BIOMATERIALS, vol. 25, 2004, pages 741 - 749, XP004471066 * |
MIRTCHI A.A. ET AL.: "Calcium phosphate cements: action of setting regulators on the properties of the beta-tricalcium phosphate-monocalcium phosphate cements", BIOMATERIALS, vol. 10, November 1989 (1989-11-01), pages 634 - 638, XP002949444 * |
NILSSON M. ET AL.: "Characterization of a novel calcium phosphate/sulphate bone cement", J. OF BIOMEDICAL MATERIALS RESEARCH, vol. 61, no. 4, 2002, pages 600 - 607, XP002229751 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8586101B2 (en) | 2001-12-20 | 2013-11-19 | Bone Support Ab | Bioresorbable bone mineral substitute comprising water-soluble X-ray contrast agent |
US9144631B2 (en) | 2003-01-27 | 2015-09-29 | Benedicte Asius | Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof |
US8662737B2 (en) | 2004-06-22 | 2014-03-04 | Bone Support Ab | Device for producing a hardenable mass |
US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
US9724449B2 (en) | 2006-05-26 | 2017-08-08 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
JP2013135975A (en) * | 2006-05-26 | 2013-07-11 | Baxter Internatl Inc | Injectable bone void filler |
US9421302B2 (en) | 2006-05-26 | 2016-08-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
US9248215B2 (en) | 2006-05-26 | 2016-02-02 | Baxter International Inc. | Injectable bone void filler |
JP2009538162A (en) * | 2006-05-26 | 2009-11-05 | バクスター・インターナショナル・インコーポレイテッド | Injectable bone void filler |
EP2117612B2 (en) † | 2007-02-14 | 2018-11-21 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
EP2117612B1 (en) | 2007-02-14 | 2015-07-29 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
EP2139507A4 (en) * | 2007-04-27 | 2012-06-06 | Unigene Lab Inc | Methods and compositions for fostering and preserving bone growth |
EP2139507A1 (en) * | 2007-04-27 | 2010-01-06 | Unigene Laboratories, Inc. | Methods and compositions for fostering and preserving bone growth |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
WO2011098438A1 (en) | 2010-02-09 | 2011-08-18 | Bone Support Ab | Preparation of bone cement compositions |
EP2353619A1 (en) | 2010-02-09 | 2011-08-10 | Bone Support AB | Preparation of Bone Cement Compositions |
CN102008748A (en) * | 2010-11-08 | 2011-04-13 | 胡钢锋 | Application of injectable degradable calcium sulfate and calcium phosphate material in repairing femoral head necrosis |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
US10994998B2 (en) | 2013-02-20 | 2021-05-04 | Bone Support Ab | Setting of hardenable bone substitute |
EP3071140A4 (en) * | 2013-11-21 | 2017-07-26 | The University of Toledo | Macroporous granules of alkaline earth phosphates using cement technology and gas evolving porogen |
WO2016007080A1 (en) * | 2014-07-10 | 2016-01-14 | Bone Support Ab | Injectable bone substitutes for augmenting implant fixation |
EP3166651A4 (en) * | 2014-07-10 | 2017-12-20 | Bone Support AB | Injectable bone substitutes for augmenting implant fixation |
GB2559761A (en) * | 2017-02-16 | 2018-08-22 | Corthotec Ltd | Composition for improved bone fracture healing |
CN107670102A (en) * | 2017-11-19 | 2018-02-09 | 赵亮 | A kind of bone Biocomposite material and preparation method and application for raising endogenous cell |
WO2019206677A1 (en) * | 2018-04-23 | 2019-10-31 | Seagles Ab | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
EP3903842A1 (en) * | 2018-04-23 | 2021-11-03 | Moroxite AB | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
Also Published As
Publication number | Publication date |
---|---|
PL1601387T3 (en) | 2009-12-31 |
CN100536932C (en) | 2009-09-09 |
AU2004218550A1 (en) | 2004-09-16 |
ES2330108T3 (en) | 2009-12-04 |
SE0300620D0 (en) | 2003-03-05 |
EP1601387A1 (en) | 2005-12-07 |
HK1079464A1 (en) | 2006-04-07 |
US20130268088A1 (en) | 2013-10-10 |
JP2006519082A (en) | 2006-08-24 |
JP4805812B2 (en) | 2011-11-02 |
CA2518104A1 (en) | 2004-09-16 |
CN1829543A (en) | 2006-09-06 |
DE602004022024D1 (en) | 2009-08-27 |
CA2518104C (en) | 2013-02-05 |
AU2004218550B2 (en) | 2009-06-04 |
PT1601387E (en) | 2009-10-19 |
EP1601387B1 (en) | 2009-07-15 |
US8420127B2 (en) | 2013-04-16 |
US20070041906A1 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1601387B1 (en) | A new bone substitute composition | |
AU2008202606B2 (en) | A new bone mineral substitute | |
EP1301219B1 (en) | A composition for an injectable bone mineral substitute material | |
CA2487994C (en) | Hydraulic cement based on calcium phosphate for surgical use | |
US8586101B2 (en) | Bioresorbable bone mineral substitute comprising water-soluble X-ray contrast agent | |
US6425949B1 (en) | Hydraulic surgical cement | |
Verron et al. | Controlling the biological function of calcium phosphate bone substitutes with drugs | |
JP4914005B2 (en) | Strontium-apatite-cement formulation and use thereof | |
EP2353619A1 (en) | Preparation of Bone Cement Compositions | |
Bumgardner et al. | Ceramic composites for bone graft applications | |
Dorozhkin | Self-Setting Formulations Calcium Orthophosphate (CaPO4) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004218550 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518104 Country of ref document: CA Ref document number: 2006507949 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004717912 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004218550 Country of ref document: AU Date of ref document: 20040305 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004218550 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048097919 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004717912 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007041906 Country of ref document: US Ref document number: 10547671 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10547671 Country of ref document: US |